The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE—This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy. RESEARCH DESIGN AND METHODS—This was a triple-blind, placebo-controlled, 30-week study conducted at 101 sites in the U.S. After a 4-week, single-blind, placebo lead-in period, 377 subjects were randomized (60% men, age 55 ± 11 years, BMI 33 ± 6 kg/m2, HbA1c 8.6 ± 1.2% [±SD]) and began 4 weeks at 5 μg subcutaneous exenatide twice daily (before breakfast and dinner; arms A and B) or placebo. Subsequently, subjects in arm B were escalated to 10 μg b.i.d. exenatide. All subjects continued sulfonylurea therapy. RESULTS—At week 30, HbA1c changes from baseline were −0.86 ± 0.11, −0.46 ± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms, respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA1c > 7% (n = 237), 41% (10 μg), 33% (5 μg), and 9% (placebo) achieved HbA1c ≤ 7% (P < 0.001). Fasting plasma glucose concentrations decreased in the 10-μg arm compared with placebo (P < 0.05). Subjects in the exenatide arms had dose-dependent progressive weight loss, with an end-of-study loss in the 10-μg exenatide arm of −1.6 ± 0.3 kg from baseline (P < 0.05 vs. placebo). The most frequent adverse events were generally mild or moderate and gastrointestinal in nature. No severe hypoglycemia was observed. CONCLUSIONS—Exenatide significantly reduced HbA1c in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea. Exenatide was generally well tolerated and was associated with weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a triple-blind, placebo-controlled 30-week clinical study involving patients with T2DM with a BMI of 33 ± 6 kg/m2, it was found that the weight loss in the EX treatment group was significantly higher than that in the control group. The primary adverse reaction to EX is nausea, suggesting that nausea may be the primary mechanism of weight loss (52).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [52]
In the citing paper
“exendin-4 appears to lower A1C levels by 0.5–1 percentage points, mainly by lowering postprandial blood glucose levels (78–81).”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [80]
In the citing paper
“It is not associated with hypoglycemia but causes a relatively high frequency of gastrointestinal disturbances, with 30–45% of treated patients experiencing one or more episodes of nausea, vomiting, or diarrhea (78–81).”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [80]
In the citing paper
“Multiple trials assessing the efficacy of exenatide have demonstrated statistically significant reductions in weight and BP [202][203][204][205] over a prolonged period but the changes in BP were small.206,207”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [204]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied linear statistical models : regression, analysis of variance, and experimental designs
Neter, J., Wasserman, W., & Kutner, M. (1974) · Andalas University Repository (Andalas University) · Cited by 2,818
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationEfficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Oral Antihyperglycemic Therapy for Type 2 Diabetes
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Cited by
Sorted by citations
Items 501–600 of 998
Treatment strategies for obesity
Wilding, J. P. H. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00333.x · Cited by 36
Marino, M. T., Costello, D. G., Baughman, R., Boss, A., Cassidy, J., D'Amico, C., van Marle, S., van Vliet, A., & Richardson, P. C. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.85 · Cited by 36
Kothare, P. A., Seger, M. E., Northrup, J., Mace, K., Mitchell, M. I., & Linnebjerg, H. (2012) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-12-8 · Cited by 35
Management and Treatment of Diabetes Mellitus
Imam, K. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_26 · Cited by 35
Guo, X. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 39
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hansen, K. B., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02086.x · Cited by 35
Gallwitz, B., KAZDA, C. M., Kraus, P., Nicolay, C., & Schernthaner, G. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0319-4 · Cited by 36
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 35
Self-citationEmerging therapies in the treatment of ‘diabesity’: beyond GLP-1
Tharakan, G., Tan, T., & Bloom, S. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.10.003 · Cited by 36
Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists
Hurren, K. M., & Pinelli, N. R. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q583 · Cited by 34
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea
Jonghe, B. C. D., Holland, R. A., Olivos, D. R., Rupprecht, L. E., Kanoski, S. E., & Hayes, M. R. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.10.031 · Cited by 35
Ellero, C., Han, J., Bhavsar, S., Cirincione, B. B., DeYoung, M. B., Gray, A. L., Yushmanova, I., & Anderson, P. W. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03085.x · Cited by 38
Self-citationBiological activity of AC3174, a peptide analog of exendin-4
Hargrove, D. M., Kendall, E. S., Reynolds, J. M., Lwin, A. N., Herich, J. P., Smith, P., Gedulin, B. R., Flanagan, S. D., Jodka, C. M., Hoyt, J. A., et al. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.021 · Cited by 35
Triplitt, C. L., Wright, A., & Chiquette, E. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.360 · Cited by 35
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Rojano‐Toimil, A., & Ciudin, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173955 · Cited by 36
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Dolovich, L., & Houlden, R. L. (2012) · Europe PMC (PubMed Central) · Cited by 33
Computational drug repositioning based on side-effects mined from social media
Nugent, T., Plachouras, V., & Leidner, J. L. (2016) · PeerJ Computer Science · doi:10.7717/peerj-cs.46 · Cited by 34
Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 33
Anti-Goblet Cell Antibodies for the Diagnosis of Autoimmune Enteropathy?
Biagi, F., Bianchi, P. I., Trotta, L., & Corazza, G. R. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.511 · Cited by 34
Exenatide as a treatment for diabetes and obesity: Implications for cardiovascular risk reduction
Mafong, D. D., & Henry, R. R. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0009-z · Cited by 34
Self-citationLiraglutide for the treatment of type 2 diabetes
Shyangdan, D., Cummins, E., Royle, P., & Waugh, N. R. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1/09 · Cited by 35
Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 34
Triplitt, C. L., McGill, J. B., Porte, D., & Conner, C. S. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-c.1 · Cited by 35
Therapies for diabetes: pramlintide and exenatide.
Jones, M. C. (2007) · PubMed · Cited by 34
Mittendorf, T., Smith‐Palmer, J., Timlin, L., Happich, M., & Goodall, G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01099.x · Cited by 34
The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit
Ryder, R. E. J., Thong, K. Y., CULL, M. L., Mills, A., Walton, C., & Winocour, P. H. (2010) · Practical Diabetes · doi:10.1002/pdi.1522 · Cited by 33
Incretin-based therapies for obesity treatment
de Mello, A. H., Prá, M. D., Cardoso, L. C., Schraiber, R. D. B., & Rezin, G. T. (2015) · Metabolism · doi:10.1016/j.metabol.2015.05.012 · Cited by 34
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 32
Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
Sekar, R., Wang, L., & Chow, B. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00018 · Cited by 33
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Halimi, S. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73400-1 · Cited by 33
The burden of type 2 diabetes: strategies to prevent or delay onset.
Iqbal, N. (2007) · PubMed Central · Cited by 33
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar, S. K., & Inzucchi, S. E. (2013) · Endocrine · doi:10.1007/s12020-013-9884-3 · Cited by 33
Moses, R. G., Round, E., Shentu, Y., Golm, G. T., O’Neill, E. A., Gantz, I., Engel, S. S., Kaufman, K. D., & Goldstein, B. J. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12351 · Cited by 32
Monami, M., Dicembrini, I., Nreu, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1054-2 · Cited by 32
Pinkney, J. H. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7313 · Cited by 31
Mathieu, C., & Bollaerts, K. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01437.x · Cited by 32
Glass, L. C., Qu, Y., Lenox, S. M., Kim, D. S., Gates, J. R., Brodows, R. G., TRAUTMANN, M. E., & Bergenstal, R. M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260862 · Cited by 31
Self-citationGut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 33
Antidiabetic Oral Treatment in Older People
Abbatecola, A. M., Paolisso, G., Corsonello, A., Bustacchini, S., & Lattanzio, F. (2009) · Drugs & Aging · doi:10.2165/11534660-000000000-00000 · Cited by 32
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 30
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 33
Boland, C. L., DeGeeter, M., Nuzum, D. S., & Tzefos, M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r444 · Cited by 32
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation
Yu, M. B., Xie, J., Landó, L. F., Kabul, S., & Swindle, R. W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.11.017 · Cited by 30
Su, N., Li, Y., Xu, T., Li, L., Kwong, J. S.-W., Du, H., Ren, K., Li, Q., Li, J., Sun, X., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.028 · Cited by 30
Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review
Bihan, H., Ng, W. L., Magliano, D. J., & Shaw, J. E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.08.011 · Cited by 31
Shiju, R., Akhil, A., Thankachan, S., Tuomilehto, J. O., Arouj, M. A., & Bennakhi, A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/3846253 · Cited by 34
Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances
Khunti, K., & Davies, M. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01186.x · Cited by 31
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
The Role of Incretin Therapy at Different Stages of Diabetes
Cernea, S. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.323 · Cited by 30
Vilsbøll, T., & Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
Aguilar, R. B. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.008 · Cited by 31
Pérez, A., Raya, P. M., de Arellano, A. R., Briones, T., Hunt, B., & Valentine, W. J. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0103-5 · Cited by 30
Wang, T., Wang, F., Zhou, J., Tang, H., & Giovenale, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2804 · Cited by 31
Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiß, S., Yin, H., Franklin, J. M., Pawar, A. M., Santella, C., Yu, O. H. Y., Renoux, C., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac021 · Cited by 30
Role of gastrointestinal hormones in feeding behavior and obesity treatment
Kairupan, T. S., Amitani, H., Cheng, K., Runtuwene, J., Asakawa, A., & Inui, A. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1118-4 · Cited by 29
Determining predictors of response to exenatide in type 2 diabetes
Anderson, S. L., Trujillo, J. M., McDermott, M., & Saseen, J. J. (2012) · Journal of the American Pharmacists Association · doi:10.1331/japha.2012.10217 · Cited by 30
Henry, R. R., Mudaliar, S. R. D., Kanitra, L., Woloschak, M., Balena, R., & for the T-Emerge 3 Study Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3253 · Cited by 30
Self-citationKolar, G. R., Grote, S., & Yosten, G. L. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12528 · Cited by 31
Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide
González, C. D., Beruto, V., Keller, G. A., Santoro, S., & Girolamo, G. D. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.887 · Cited by 30
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 30
Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 29
Management of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
GLP-1R activation for the treatment of stroke: Updating and future perspectives
Darsalia, V., Nathanson, D., Nyström, T., Klein, T., Sjöholm, Å., & Patrone, C. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9285-9 · Cited by 30
Kuritzky, L., Umpierrez, G. E., Ekoé, J. M., Mancillas‐Adame, L. G., & Landó, L. F. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2821 · Cited by 30
Simmons, J. H., Shoemaker, A. H., & Roth, C. L. (2012) · Hormone Research in Paediatrics · doi:10.1159/000339469 · Cited by 29
Bayesian Adaptive Dose-Finding Studies with Delayed Responses
Fu, H., & Manner, D. H. (2010) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400903315740 · Cited by 29
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes
Schnabel, C. A., Wintle, M. E., & Kolterman, O. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.69 · Cited by 29
Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
Khan, M. A., Ouyang, J., Perkins, K., Nair, S., & Joseph, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/162718 · Cited by 32
GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes
Holst, J. J., & Seino, Y. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.017 · Cited by 29
Campbell, R. K., & White, J. R. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708317870 · Cited by 31
Incretin Therapy – Present and Future
Garber, A. J. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.307 · Cited by 29
An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 28
Bhushan, R., Elkind-Hirsch, K. E., Bhushan, M., Butler, W. J., Duncan, K., & Marrioneaux, O. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0090 · Cited by 28
Wang, L., Liu, Y., Yang, J., Zhao, H., Ke, J., Tian, Q., Zhang, L., Wen, J., Wei, R., & Hong, T. (2014) · Endocrinology · doi:10.1210/en.2014-1218 · Cited by 28
Hepatotoxicity of Cardiovascular and Antidiabetic Drugs
Marzio, D. H., & Navarro, V. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00029-7 · Cited by 29
Yasuda, H., Ohashi, A., Nishida, S., Kamiya, T., Suwa, T., Hara, H., Takeda, J., Itoh, Y., & Adachi, T. (2016) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.16-26 · Cited by 28
GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes
Bailey, J., Coucha, M. M., Bolduc, D. R., Burnett, F. N., Barrett, A. C., Ghaly, M., & Abdelsaid, M. A. (2022) · Diabetologia · doi:10.1007/s00125-022-05730-5 · Cited by 27
Gliptins: a new class of oral hypoglycaemic agent
Chahal, H., & Chowdhury, T. A. (2007) · QJM · doi:10.1093/qjmed/hcm081 · Cited by 28
Gastrointestinal peptides controlling body weight homeostasis
Zerón, H. M., López, M., & Diéguez, C. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.11.009 · Cited by 29
Li, X. C., & Zhuo, J. L. (2007) · Clinical Science · doi:10.1042/cs20070040 · Cited by 27
Can Newer Therapies Delay the Progression of Type 2 Diabetes Mellitus?
Horton, E. S. (2008) · Endocrine Practice · doi:10.4158/ep.14.5.625 · Cited by 28
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Clinical Diabetes · doi:10.2337/diaclin.27.1.4 · Cited by 29
Self-citationPreumont, V., Hermans, M. P., Brichard, S. M., & Buysschaert, M. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.02.001 · Cited by 27
Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations
Liang, N.-C., Bello, N. T., & Moran, T. H. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.16 · Cited by 27
Nikfar, S., Abdollahi, M. R., & Salari, P. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3g883 · Cited by 27
Hanefeld, M. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000225 · Cited by 28
Bayesian indirect and mixed treatment comparisons across longitudinal time points
Ding, Y., & Fu, H. (2012) · Statistics in Medicine · doi:10.1002/sim.5688 · Cited by 27
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Orme, M. E., Nguyen, H. P., Lu, J., & Thomas, S. V. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s116810 · Cited by 27
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 30
2. DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Wiedeman, P. E. (2007) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(06)45502-8 · Cited by 25
Campbell, I. W. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02292.x · Cited by 25
Optimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say?
Mathur, S., Zammitt, N. N., & Frier, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0247-7 · Cited by 29
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Montanya, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.692777 · Cited by 27
2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV
Haffner, C. D., McDougald, D. L., Reister, S. M., Thompson, B. D., Conlee, C., Fang, J., Bass, J. Y., Lenhard, J. M., Croom, D. K., Secosky-Chang, M. B., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.050 · Cited by 28
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
Penfornis, A., Borot, S., & Raccah, D. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73399-8 · Cited by 27
Exenatide: a novel treatment of Type 2 diabetes
Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26
Triplitt, C. L., Glass, L. C., Miyazaki, Y., Wajcberg, E., Gastaldelli, A., Filippis, E. D., Cersósimo, E., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc06-0564 · Cited by 28
Metadata
- Authors
- Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of California San Diego (US)
- Amylin Pharmaceuticals, San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-11-01
- Volume
- 27
- Issue
- 11
- Pages
- 2628-2635
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1986085856
- Cited by
- 1,346
- References
- 38
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 17 · 2023: 7 · 2022: 13 · 2021: 24 · 2020: 20 · 2019: 16 · 2018: 19 · 2017: 30 · 2016: 53 · 2015: 46 · 2014: 76 · 2013: 79 · 2012: 120
- FWCI
- 56.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Amylin Pharmaceuticals
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, exendin-4, type 2 diabetes, sulfonylureas, glycemic control, HbA1c, incretin mimetics, dose escalation, weight loss, fasting blood glucose, gastrointestinal adverse effects, hypoglycemia, combination therapy, long-term efficacy and safety
- MeSH terms
- Exenatide, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Fasting, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Peptides, Proinsulin, Sulfonylurea Compounds, Venoms, Weight Loss, Treatment Failure, Retreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
